Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.
The concentration of substance-P-like immunoreactivity (SPLI) and somatostatin-like immunoreactivity (SLI) in the lumbar spinal fluid of senile parkinsonian patients (mean age 77.6 +/- 6.7 years) and senile control patients (mean age 83.5 +/- 5.6 years) were determined by specific radioimmunoassays. Mean SPLI and SLI levels in the control group were 8.1 +/- 2.0 (SD) and 32.5 +/- 12.0 fmol/ml, respectively. The mean SPLI levels were not significantly different in the groups. The mean SLI level was significantly lower in the group of patients with Parkinson's disease (19.8 +/- 9.0 fmol/ml). A comparison with results in patients with senile dementia of Alzheimer type (SDAT) shows that, in addition to clinical and pathological correlations, Parkinson's disease of late onset may share a deficit in somatostatinergic neuromodulation with SDAT.
Cramer
H
H
Department of Neurology and Clinical Neurophysiology, University of Freiburg, FRG.
Rissler
K
K
Rösler
N
N
Strubel
D
D
Schaudt
D
D
Kuntzmann
F
F
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid*; D013004:Somatostatin / Q000134:cerebrospinal fluid*; D013373:Substance P / Q000134:cerebrospinal fluid*
D013373:Substance P; D013004:Somatostatin